Abstract |
The toxic effect and anti- tumor activity of B-3839, a new molecular combination of pyrimidine antimetabolite 5-fluorouracil (5-FU) with the alkylating agent N-Chloroethyl-N-nitrosourea ( BCNU), was compared to that of BCNU and 5-FU given alone and in physical combination. The tumor inhibitory effect of B-3839 was similar to that of BCNU given alone or combined with a low dose of 5-FU in the i.m. Walker tumor model. Furthermore, the bone marrow toxicity of BCNU was not significantly altered by either form of combination with 5-FU. The intestinal side effects, evaluated by measuring the decrease of marker enzyme ( thymidine kinase, xanthine oxidase, alkaline phosphatase, sucrase, maltase) activities in isolated enterocytes, were dose-dependent and moderate. A significant, more than 30%, decrease occurred only if BCNU and 5-FU were given simultaneously or as B-3839. The molecular combination of the two drugs does not provide any additional advantage over their physical combination.
|
Authors | N Prajda, J Kralovánszky, S Somfai-Relle, F Gál, S Kerpel-Fronius |
Journal | In vivo (Athens, Greece)
(In Vivo)
1988 Mar-Apr
Vol. 2
Issue 2
Pg. 151-4
ISSN: 0258-851X [Print] Greece |
PMID | 2979832
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Nitrosourea Compounds
- B 3839
- Fluorouracil
- Carmustine
|
Topics |
- Animals
- Antineoplastic Agents
(therapeutic use)
- Carcinoma 256, Walker
(drug therapy)
- Carmustine
(therapeutic use, toxicity)
- Digestive System
(drug effects, pathology)
- Fluorouracil
(analogs & derivatives, therapeutic use, toxicity)
- Male
- Nitrosourea Compounds
(therapeutic use, toxicity)
- Rats
- Rats, Inbred Strains
|